Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline explore long-term treatment with lecanemab and estimated time savings over 10 years, safety and potential benefits of subcutaneous administration of lecanemab for initiation dosing Oral and poster presentations also include data on the effects of lecanemab on soluble amyloid-β protofibrils and insights from real-world clinical practice studies, including the ALZ-NET Registry NUTLEY, N.J., Nov. 18, 2025 /PRNewswire/ -- Eisai

Designation underscores the potential for VS-041 to address a significant unmet medical need and potentially improve diagnosis by utilizing a serum biomarker VS-041 is being evaluated in a Phase 1c study of participants with HFpEF and elevated serum endotrophin ENCINITAS, Calif., and WROCLAW, Poland, Nov. 18, 2025 /PRNewswire/ -- Vasa Therapeutics ("Vasa"), a private, clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, today announced that

NEW YORK and NEW HAVEN, Conn., Nov. 18, 2025 /PRNewswire/ -- Triomics, an oncology-focused generative AI company, today announced it will expand the use of Triomics' AI-powered clinical-trial screening and feasibility system across the entire portfolio of active oncology clinical trials at Yale Cancer Center (YCC) and Smilow Cancer Hospital. At leading cancer centers such as YCC, clinical and research teams work with narrative-heavy patient charts that span clinician notes, pathology and radiolo

Longest Survival in the World Reported to Date for Multiple Myeloma Patients No Patient Underwent Frontline Autologous Stem Cell Transplant No Patient Was Treated with CAR T-Cell Therapy or Bispecific Antibodies WEST HOLLYWOOD, Calif., Nov. 18, 2025 /PRNewswire/ -- Berenson Cancer Center published survival data analyzed by the Institute for Myeloma & Bone Cancer Research of 175 consecutive and unselected patients with multiple myeloma in the journal Haematologica. All patients with multipl

The FDA clearances expand Vesalio's thrombectomy portfolio to support its growth strategy in the rapidly expanding multi-billion dollar global thrombectomy market. PLANO, Texas, Nov. 18, 2025 /PRNewswire/ -- Vesalio, a leader in innovative thrombectomy solutions, today announced two new FDA 510(k) clearances for its aspiration devices, designed for peripheral and neurovascular applications. These clearances mark a key milestone in Vesalio's evolution toward providing a complete suite of thrombe

BOSTON, Nov. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with the Institute for Genomic Biology at the University of Illinois Urbana-Champaign on a five-year initiative funded by the Advanced Research Projects Agency for Health (ARPA-H). The collaboration, Microbe/phage Investigation for Generalized Health TherapY (MIGHTY), aims to develop innovative new treatments for oral health by leveraging Ginkgo's advanced capabilities in working with complex microb

The objective of this new phase of collaboration with Leiden University Medical Center (LUMC) is to further advance the recently completed and published pioneering research to determine whether the modes of DNA polymerase pol IIIC (PolC) action and resistance are conserved across important species of Gram-positive multidrug resistant organisms The previous LUMC-Acurx Health~Holland project successfully elucidated the structure of PolC from E. faecium, a critical Gram-positive human pathogen, in

HEFEI, China, Nov. 18, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals announced today that the company will deliver a poster presentation to highlight the Phase I clinical trial results of epaldeudomide (KPG-818) for the treatment of hematological malignancies at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida, USA. Poster Title: KPG-818, a Novel Cereblon (CRBN) Modulator, in Patients with Hematological Malignancies: Results of a

PHILADELPHIA, Nov. 18, 2025 /PRNewswire/ -- BlueWhale Bio, Inc., a company dedicated to transforming immune cell therapy manufacturing, today announced that its Synecta™ cell-derived nanoparticle (CDNP) platform for immune cell activation has been granted Advanced Manufacturing Technology (AMT) designation from the U.S. Food and Drug Administration (FDA). Synecta leverages cell-derived nanoparticles (CDNPs) that mimic the natural activation of immune cells, producing higher-quality cells through

Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as planned More than half of planned participants have completed dosing with no dose reductions, discontinuations, drug-related SAEs, loss of consciousness, or excessive sedation reported Topline results are on track for the second quarter of 2026 SALT LAKE CITY, Nov. 18, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary te